Carregant...
Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation...
Guardat en:
| Publicat a: | Br J Pharmacol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7323156/ https://ncbi.nlm.nih.gov/pubmed/32557557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15164 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|